Chesley Taft & Associates’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$53.3M Sell
209,735
-977
-0.5% -$228K 2.07% 11
2026
Q1
$51.5M Sell
210,712
-2,191
-1% -$510K 2.15% 9
2025
Q4
$44.1M Buy
212,903
+14,776
+7% +$2.92M 1.74% 12
2025
Q3
$36.7M Sell
198,127
-5,244
-3% -$898K 1.56% 17
2025
Q2
$31.1M Sell
203,371
-1,295
-0.6% -$199K 1.39% 20
2025
Q1
$33.9M Sell
204,666
-2,669
-1% -$418K 1.64% 13
2024
Q4
$30M Sell
207,335
-1,505
-0.7% -$233K 1.39% 18
2024
Q3
$33.8M Sell
208,840
-2,088
-1% -$333K 1.61% 15
2024
Q2
$30.8M Buy
210,928
+2,373
+1% +$353K 1.55% 16
2024
Q1
$33M Buy
208,555
+507
+0.2% +$80.7K 1.69% 14
2023
Q4
$32.6M Sell
208,048
-2,893
-1% -$444K 1.83% 13
2023
Q3
$32.9M Sell
210,941
-1,983
-0.9% -$327K 2.13% 7
2023
Q2
$35.2M Sell
212,924
-12,640
-6% -$2.04M 2.16% 6
2023
Q1
$35M Sell
225,564
-1,122
-0.5% -$181K 2.29% 6
2022
Q4
$40M Buy
226,686
+507
+0.2% +$87.5K 2.76% 5
2022
Q3
$36.9M Sell
226,179
-1,009
-0.4% -$171K 2.72% 6
2022
Q2
$40.3M Sell
227,188
-530
-0.2% -$94.4K 2.75% 5
2022
Q1
$41M Sell
227,718
-6,503
-3% -$1.11M 2.4% 7
2021
Q4
$40.1M Buy
234,221
+2,429
+1% +$398K 2.07% 10
2021
Q3
$37.4M Sell
231,792
-232
-0.1% -$39.6K 2.13% 9
2021
Q2
$38.2M Sell
232,024
-1,649
-0.7% -$273K 2.2% 7
2021
Q1
$38.2M Buy
233,673
+2,469
+1% +$400K 2.28% 7
2020
Q4
$36.4M Sell
231,204
-124
-0.1% -$18.3K 2.32% 8
2020
Q3
$34.4M Buy
231,328
+5,547
+2% +$821K 2.45% 7
2020
Q2
$31.8M Buy
225,781
+12,468
+6% +$1.82M 2.42% 6
2020
Q1
$28M Sell
213,313
-2,875
-1% -$408K 2.55% 7
2019
Q4
$31.5M Buy
216,188
+17,029
+9% +$2.31M 2.27% 9
2019
Q3
$25.8M Sell
199,159
-2,006
-1% -$264K 2% 11
2019
Q2
$28M Sell
201,165
-12
-0% -$1.66K 2.19% 8
2019
Q1
$28.1M Sell
201,177
-2,433
-1% -$326K 2.34% 6
2018
Q4
$26.3M Sell
203,610
-116
-0.1% -$16.2K 2.54% 5
2018
Q3
$28.1M Buy
203,726
+1,817
+0.9% +$241K 2.24% 5
2018
Q2
$24.5M Sell
201,909
-4,127
-2% -$515K 2.11% 5
2018
Q1
$26.4M Buy
206,036
+291
+0.1% +$39.3K 2.35% 4
2017
Q4
$28.7M Sell
205,745
-1,052
-0.5% -$147K 2.43% 4
2017
Q3
$26.9M Buy
206,797
+1,258
+0.6% +$167K 2.32% 4
2017
Q2
$27.2M Buy
205,539
+6,245
+3% +$797K 2.46% 4
2017
Q1
$24.8M Buy
199,294
+867
+0.4% +$104K 2.34% 5
2016
Q4
$22.9M Sell
198,427
-1,538
-0.8% -$178K 2.26% 6
2016
Q3
$23.6M Sell
199,965
-3,450
-2% -$419K 2.38% 7
2016
Q2
$24.7M Sell
203,415
-30
-0% -$3.41K 2.53% 5
2016
Q1
$22M Buy
203,445
+268
+0.1% +$27.7K 2.32% 7
2015
Q4
$20.9M Sell
203,177
-22,279
-10% -$2.24M 2.19% 8
2015
Q3
$21M Buy
225,456
+1,710
+0.8% +$165K 2.3% 7
2015
Q2
$21.8M Sell
223,746
-6,395
-3% -$640K 2.22% 5
2015
Q1
$23.2M Sell
230,141
-331
-0.1% -$33.7K 2.38% 3
2014
Q4
$24.1M Sell
230,472
-1,569
-0.7% -$165K 2.44% 2
2014
Q3
$24.7M Sell
232,041
-1,673
-0.7% -$174K 2.59% 1
2014
Q2
$24.5M Sell
233,714
-1,689
-0.7% -$171K 2.53% 3
2014
Q1
$23.1M Sell
235,403
-335
-0.1% -$31.1K 2.48% 3
2013
Q4
$21.6M Buy
235,738
+3,957
+2% +$365K 2.15% 3
2013
Q3
$20.1M Sell
231,781
-1,653
-0.7% -$148K 2.19% 3
2013
Q2
$20M Buy
+233,434
New +$19.8M 2.32% 4

Other funds holding JNJ

Chesley Taft & Associates's JNJ Position: Q2 2026 in Review

Chesley Taft & Associates reduced its Johnson & Johnson (JNJ) stake by 0.46% in Q2 2026, selling an estimated $228K and leaving 209,735 shares worth $53.3M. The position accounts for 2.07% of the portfolio, ranked #11.

Chesley Taft & Associates first reported a position in JNJ in Q2 2013 and has held it in 53 quarters since. 899 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Chesley Taft & Associates held 209,735 shares of Johnson & Johnson worth $53.3M as of Q2 2026.
  • Chesley Taft & Associates sold 977 Johnson & Johnson shares in Q2 2026, an estimated $228K.
  • Johnson & Johnson made up 2.07% of Chesley Taft & Associates's portfolio in Q2 2026, its #11 holding.
  • Chesley Taft & Associates first reported a position in Johnson & Johnson in Q2 2013 and has held it in 53 quarters since.
  • 899 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Chesley Taft & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.